Перегляд за автором "Yurchenko, M."

Сортувати за: Порядок: Результатів:

  • Yurchenko, M.; Shlapatska, L.M.; Romanets, O.L.; Ganshevskiy, D.; Kashuba, E.; Zamoshnikova, A.; Ushenin, Yu.V.; Snopok, B.A.; Sidorenko, S.P. (Experimental Oncology, 2011)
    Aim of this article is to study upstream and downstream events in CD150-mediated Akt signaling pathway in normal human B cells, EBV-transformed lymphoblastoid (LCL) and malignant Hodgkin’s lymphoma (HL) B cell lines.
  • Yenamandra, S.P.; Lundin, A.; Arulampalam, V.; Yurchenko, M.; Pettersson, S.; Klein, G.; Kashuba, E. (Experimental Oncology, 2009)
    Background: Infection of human B cells with Epstein—Barr virus (EBV) induces metabolic activation, morphological transformation, cell proliferation and eventual immortalization. Aim: To identify the nuclear receptors, ...
  • Yurchenko, M.; Sidorenko, S.P. (Experimental Oncology, 2010)
    The hallmark of Hodgkin’s lymphoma (HL) are mononucleated Hodgkin’s cells and multinucleated Reed-Sternberg (HRS) cells, which usually account for only about 1% of cells in the tumor tissue. The majority of HRS cells in ...
  • Yurchenko, M.; Shlapatska, L.M.; Sidorenko, S.P. (Experimental Oncology, 2012)
    CD95, also called Fas or APO-1, was the first death receptor (DR) identified and characterized. Studies on CD95 receptor signaling revealed the versatile principles of cell fate regulation via DR. DRs could exert both pro- ...